Neurobiological Technologies, Inc.
NTII · OTC
6/30/2010 | 6/30/2009 | 6/30/2008 | 6/30/2007 | |
|---|---|---|---|---|
| Revenue | – | $26 | $15 | $18 |
| % Growth | – | 78.5% | -16.5% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $26 | $15 | $17 |
| % Margin | – | 99.5% | 98.6% | 98.7% |
| R&D Expenses | – | $18 | $25 | $27 |
| G&A Expenses | – | $5 | $0 | $0 |
| SG&A Expenses | – | $5 | $7 | $6 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $23 | $31 | $33 |
| Operating Income | – | $3 | -$17 | -$16 |
| % Margin | – | 13.2% | -113.1% | -88.3% |
| Other Income/Exp. Net | – | -$0 | $0 | $1 |
| Pre-Tax Income | – | $3 | -$16 | -$14 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | – | $3 | -$16 | -$14 |
| % Margin | – | 11.9% | -110.6% | -79.9% |
| EPS | – | 0.12 | -0.84 | -3.26 |
| % Growth | – | 114.3% | 74.2% | – |
| EPS Diluted | – | 0.12 | -0.84 | -3.26 |
| Weighted Avg Shares Out | – | 27 | 19 | 4 |
| Weighted Avg Shares Out Dil | – | 27 | 19 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $1 | $1 | $0 |
| Interest Expense | – | $0 | $2 | $0 |
| Depreciation & Amortization | – | $0 | $0 | $0 |
| EBITDA | – | $3 | -$16 | -$15 |
| % Margin | – | 12.4% | -111.7% | -87% |